Daily Endocrinology Research Analysis
Three impactful endocrinology papers stand out today: a genotype-first study shows low penetrance of pathogenic ALPL variants for hypophosphatasia, reframing risk communication; basic work identifies nucleosides released by adipose tissue as candidate mediators linking obesity to inflammation; and a UK Biobank cohort clarifies how guideline-level physical activity mitigates mortality risk across insulin resistance strata.
Summary
Three impactful endocrinology papers stand out today: a genotype-first study shows low penetrance of pathogenic ALPL variants for hypophosphatasia, reframing risk communication; basic work identifies nucleosides released by adipose tissue as candidate mediators linking obesity to inflammation; and a UK Biobank cohort clarifies how guideline-level physical activity mitigates mortality risk across insulin resistance strata.
Research Themes
- Genotype-first risk stratification in metabolic bone disease
- Adipose–immune crosstalk via extracellular nucleosides
- Dose–response of physical activity across insulin resistance levels
Selected Articles
1. Hypophosphatasia: Low Penetrance of Pathogenic and Likely-Pathogenic ALPL Variants Identified Through an Unselected Biorepository.
In an unselected cohort of 37,147 genomes, pathogenic/likely pathogenic ALPL variants were present in 0.3% of individuals, yet only 12.9% of EHR-linked carriers met hypophosphatasia diagnostic criteria and 65.7% had low ALP. Mobility issues occurred earlier in carriers, supporting low penetrance and the need for phenotype-driven management rather than genotype alone.
Impact: This large genotype-first study challenges assumptions about ALPL variant penetrance and prevents overdiagnosis of hypophosphatasia by demonstrating that most carriers do not meet clinical criteria.
Clinical Implications: Clinicians should avoid diagnosing HPP based on genotype alone; assess serum ALP and clinical features and target therapy (e.g., asfotase alfa) to those meeting consensus criteria. Genetic counseling should emphasize low penetrance.
Key Findings
- Among 37,147 genomes, 0.3% (n=109) harbored pathogenic/likely pathogenic ALPL variants; c.571G>A accounted for 67.9%.
- In 70 EHR-linked carriers, low ALP was present in 65.7% and only 12.9% met hypophosphatasia diagnostic criteria.
- Carriers showed earlier progression of mobility issues (median age 73 vs 82 years; p=0.03) compared to non-carriers; 3.4% of non-carriers met HPP criteria.
Methodological Strengths
- Genotype-first approach in a large, unselected biorepository (n=37,147).
- Linkage to electronic health records enabling objective phenotype assessment against consensus criteria.
Limitations
- Retrospective design with reliance on EHR completeness and potential misclassification.
- Limited biochemical and imaging data across all carriers; single-center setting may limit generalizability.
Future Directions: Prospective, multi-center phenotyping of ALPL variant carriers with standardized biochemical and skeletal assessments to refine penetrance estimates and risk prediction.
Hypophosphatasia (HPP) is a heritable multisystem disorder caused by pathogenic variants in the tissue non-specific alkaline phosphatase (ALP)-coding gene ALPL. The genotype-phenotype correlation in heterozygous adults with HPP remains incompletely understood. In this genotype-based study, we aimed to measure the prevalence of pathogenic or likely-pathogenic ALPL variants and test the hypothesis that HPP penetrance is low in adult carriers. A total of 37,147 genomes from unselected individuals visiting a tertiary care, academic medical center were investigated. Variants classified as pathogenic or likely-pathogenic were observed with a prevalence of 0.3% (n=109) or 1/341. Variant c.571G>A was most frequent (67.9%). A subset of 70 individuals had linked electronic health records (EHRs) and were termed ALPL+. All 70 ALPL+ individuals showed mild, mainly neurological, symptoms often reported in adults with HPP. However, low serum ALP, a hallmark of HPP, was found in only 65.7% (38/70) of ALPL+ individuals, and 12.9% (9/70) met the diagnostic criteria for HPP based on consensus guidelines, thus complete penetrance was low. Compared to controls lacking pathogenic or likely-pathogenic variants (ALPL-), the ALPL+ individuals had a higher probability of progression for mobility issues (median age 73 years ALPL+ vs. 82 years ALPL-, p=0.03), as well as a similar probability of progression for fatigue, arthritis or dental problems. Unexpectedly, 3.4% (5/148) of individuals in the ALPL- group met the diagnostic criteria for HPP, possibly due to unidentified variants or non-ALPL genetic factors. Overall, the data support our hypothesis and aids the management of carries of pathogenic ALPL variants.
2. Adipose Tissue Releases Nucleosides.
Mouse adipocytes release a broad spectrum of nucleosides, and obese adipose tissue releases more than lean adipose tissue. Given that extracellular nucleosides can activate toll-like and purinergic receptors, these data implicate nucleoside signaling as a potential mediator linking adiposity to inflammation and insulin resistance.
Impact: Identifying nucleosides as adipose-derived signals provides a novel mechanistic axis for obesity-related inflammation, opening new therapeutic targets beyond traditional cytokine pathways.
Clinical Implications: While preclinical, these findings support exploring pharmacologic modulation of extracellular nucleoside signaling (e.g., purinergic receptor antagonism) to reduce obesity-associated inflammation and insulin resistance.
Key Findings
- Cultured mouse adipocytes released multiple nucleosides used in RNA/DNA.
- Obese mouse adipose tissue released more nucleosides than non-obese control adipose tissue.
- Rationale established for extracellular nucleosides as adipose-derived inflammatory mediators via toll-like and purinergic receptors.
Methodological Strengths
- Direct quantification of nucleoside release from adipocytes and adipose tissue.
- Comparative analysis between obese and non-obese adipose tissue.
Limitations
- Preclinical mouse models and in vitro systems limit direct human translatability.
- Causality between nucleoside release and metabolic disease outcomes was not tested.
Future Directions: Validate nucleoside release patterns in human adipose tissue and test whether modulating purinergic signaling ameliorates metabolic inflammation in vivo.
It remains unclear how excess adipose tissue in obesity leads to inflammation, insulin resistance and other comorbidities. Extracellular nucleosides can induce inflammation through the activation of immune cell toll-like and purinergic receptors. The present study quantified nucleoside release from adipocytes and adipose tissue. Cultured mouse adipocytes released many nucleosides used in RNA/DNA. Adipose tissue from obese mice released more nucleosides than that from control non-obese mice
3. Effects of moderate-to-vigorous physical activity on the associations between an insulin resistance surrogate and incident cardiovascular disease and all-cause mortality: a UK Biobank cohort study.
In 299,928 adults over ~14 years, MVPA exhibited a reverse J-shaped dose–response for incident CVD (threshold ~262 min/week) and an L-shaped association for all-cause mortality (plateau ~217 min/week). Elevated TyG-WHtR independently increased risk, and guideline-recommended MVPA (150–299 min/week) conferred mortality benefit, particularly among those with moderate insulin resistance.
Impact: This large-scale cohort refines the dose–response of MVPA across insulin resistance strata, reinforcing guideline targets and informing individualized counseling for cardiometabolic risk reduction.
Clinical Implications: Advise at least 150–299 min/week of MVPA for adults with insulin resistance; additional volume beyond ~220–260 min/week yields diminishing returns for mortality. Emphasize MVPA to offset TyG-WHtR–related risk while pursuing comprehensive risk factor control.
Key Findings
- MVPA showed a reverse J-shaped association with incident CVD (cutoff ~261.7 min/week) and an L-shaped association with all-cause mortality (plateau ~217.0 min/week).
- Higher TyG-WHtR was independently associated with increased incident CVD and all-cause mortality risks.
- Guideline-recommended MVPA (150–299 min/week) reduced mortality risk, with a significant interaction observed for mortality in those with moderate TyG-WHtR (HR for interaction 0.89; 95% CI 0.81–0.97).
Methodological Strengths
- Very large prospective cohort with long follow-up and robust event counts.
- Comprehensive modeling including MVPA–IR interaction and dose–response characterization.
Limitations
- Observational design with potential residual confounding and likely self-reported MVPA.
- TyG-WHtR is a surrogate for insulin resistance and may not capture all aspects of metabolic dysfunction.
Future Directions: Test whether tailored MVPA prescriptions improve outcomes across IR strata in randomized pragmatic trials, and validate device-measured activity thresholds.
BACKGROUND: Moderate-to-vigorous physical activity (MVPA) and insulin resistance (IR) are associated with cardiovascular disease (CVD). It remains unclear whether different durations of MVPA can modify the associations of the triglyceride glucose-waist height ratio (TyG-WHtR) index, a surrogate for IR, with incident CVD and all-cause mortality, and whether MVPA levels beyond guideline recommendations provide additional benefit. METHODS: This cohort study included 299,928 adults from the UK Biobank study who were free of prevalent CVD at baseline and had complete data on MVPA, the TyG-WHtR index, and relevant covariates. The Cox proportional hazards model was used to assess the independent and joint associations of MVPA and TyG-WHtR with incident CVD and all-cause mortality. A product term of MVPA (< 150, 150-299, 300-599, and ≥ 600 min/week) and TyG-WHtR (tertiles) was included in the model to assess multiplicative interaction. RESULTS: During a median follow-up of 13.8 and 13.6 years, 27,342 CVD cases and 21,258 deaths were observed. MVPA demonstrated a reverse J-shaped association with incident CVD, with a cutoff point at 261.71 min/week, whereas an L-shaped association was observed for all-cause mortality, with risk reduction plateauing at 217.00 min/week. Elevated TyG-WHtR was positively associated with increased risks of incident CVD and all-cause mortality. No significant interaction was found for incident CVD, whereas an interaction effect was observed between 150-299 min/week MVPA and TyG-WHtR tertile 2 on all-cause mortality (HR for interaction, 0.89; 95% CI, 0.81-0.97; CONCLUSIONS: Our findings highlight the importance of engaging in guideline-recommended MVPA (150-299 min/week) to reduce all-cause mortality risk, particularly among individuals with moderate IR (TyG-WHtR, 7.01-8.03), who are more likely to benefit. Furthermore, the protective effects of higher levels of MVPA against IR-related risks were consistent with those of guideline-recommended MVPA.